SCHEDULE: Ventyx Biosciences Acquired by Eli Lilly for Cash

Ventyx Biosciences, Inc. has entered into a definitive merger agreement to be acquired by Eli Lilly and Company for $14.00 per common share in cash.

Summary

• Ventyx Biosciences, Inc. (the "Issuer") has entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company ("Parent") and RYLS Merger Corporation ("Merger Sub").
• Pursuant to the Merger Agreement, Merger Sub will merge with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent.
• Each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the Merger will be converted into the right to receive $14.00 per share in cash, without interest and less any applicable tax withholding.
• Each share of the Issuer's preferred stock issued and outstanding immediately prior to the effective time will be converted into the right to receive $1,400.00 per share in cash, without interest.
• Outstanding Issuer Stock Options will be cancelled in exchange for a cash payment equal to the product of the total number of shares subject to the option and the excess of $14.00 over the exercise price, provided the exercise price is less than $14.00. Options with an exercise price equal to or greater than $14.00 will be cancelled without consideration.
• Outstanding Issuer Restricted Stock Units (RSUs) will be cancelled in exchange for a cash payment equal to the product of the total number of shares subject to the RSU and $14.00.
• Raju Mohan, the reporting person, and certain other parties have entered into Voting and Support Agreements with Parent, agreeing to vote their shares in favor of the Merger and to refrain from transferring their shares.
• Raju Mohan beneficially owns 4,387,682 shares of common stock, representing 6.0% of the class, which includes 2,372,863 shares held directly and 2,014,819 shares issuable pursuant to options exercisable within 60 days of January 7, 2026.

Sentiment

Score: 8

Explanation: The filing announces a definitive merger agreement where Ventyx Biosciences will be acquired for cash, providing a clear and positive outcome for shareholders and equity award holders. The fixed cash price offers certainty and liquidity, which is generally viewed favorably, especially in the context of a strategic acquisition by a major pharmaceutical company like Eli Lilly.

Positives

• Shareholders will receive a fixed cash consideration of $14.00 per common share, providing immediate liquidity and a defined return on their investment.
• Preferred shareholders will receive a substantial cash payment of $1,400.00 per share.
• Holders of in-the-money stock options and restricted stock units will receive cash payments, monetizing their equity awards.
• The acquisition by a major pharmaceutical company like Eli Lilly provides a clear and strategic exit for Ventyx Biosciences and its investors.

Negatives

• The merger will result in Ventyx Biosciences ceasing to be an independent publicly traded company, eliminating future growth potential for existing shareholders.
• Shareholders will no longer participate in any potential future upside or development of Ventyx's pipeline under Eli Lilly's ownership.
• Stock options with an exercise price equal to or greater than $14.00 will be cancelled without any consideration, resulting in a loss for those holders.

Risks

• The Merger is subject to the satisfaction or waiver of various conditions outlined in the Merger Agreement, meaning the transaction is not yet guaranteed to close.
• The Voting and Support Agreement, which secures key shareholder votes, terminates under certain circumstances, including the termination of the Merger Agreement, which could introduce uncertainty.

Future Outlook

The filing indicates a definitive agreement for Ventyx Biosciences to be acquired by Eli Lilly and Company, with the Issuer becoming a wholly owned subsidiary. The future outlook for Ventyx as an independent entity is therefore limited to the completion of this merger.

Industry Context

This acquisition by Eli Lilly and Company of Ventyx Biosciences reflects a broader trend of larger pharmaceutical companies acquiring smaller biotechnology firms to expand their pipelines and intellectual property, particularly in areas of therapeutic innovation. Such mergers often aim to consolidate promising drug candidates and leverage the acquiring company's extensive resources for development and commercialization.

Comparison to Industry Standards

• The cash-only consideration is a common structure for acquisitions, offering certainty to target shareholders, which is a standard practice in the industry.
• The acquisition price of $14.00 per common share would need to be compared to Ventyx's recent trading prices and analyst price targets to assess its premium relative to industry benchmarks for similar biotech acquisitions.
• Eli Lilly's acquisition strategy often targets companies with innovative drug candidates, similar to its past acquisitions like Dice Therapeutics for $2.4 billion or Prevail Therapeutics for $1.04 billion, indicating a consistent focus on pipeline expansion.

Related Party Transactions

• The Voting and Support Agreement entered into by Raju Mohan (a reporting person) and certain other parties with Parent could be considered a related party transaction in the context of the merger, as it aligns the interests of significant shareholders with the acquiring entity to facilitate the transaction.

Stakeholder Impact

• Shareholders: Will receive $14.00 per common share in cash, providing immediate liquidity and a defined return on investment.
• Employees (with equity awards): Holders of in-the-money stock options and RSUs will receive cash payments, monetizing their equity.
• Company (Ventyx Biosciences): Will cease to be an independent public entity and will become a wholly owned subsidiary of Eli Lilly, integrating its operations and pipeline into a larger pharmaceutical company.
• Eli Lilly and Company: Will acquire Ventyx Biosciences, potentially expanding its therapeutic pipeline and market presence.

Next Steps

• Satisfaction or waiver of conditions outlined in the Merger Agreement.
• Merger Sub will merge with and into the Issuer.
• The Issuer will survive as a wholly owned subsidiary of Eli Lilly and Company.
• Cash payments will be made to holders of common stock, preferred stock, stock options, and RSUs at the effective time of the Merger.

Key Dates

Recommendation

The filing announces a definitive merger agreement where Ventyx Biosciences will be acquired by Eli Lilly for $14.00 per common share in cash. For investors, this represents a clear, fixed, and certain return. Assuming the current market price is below $14.00 (which is typical for an announced acquisition, reflecting the time value of money and closing risk), buying the stock would allow an investor to capture the spread between the current price and the $14.00 acquisition price. This is a low-risk arbitrage opportunity, making it a strong buy for those looking to capture the merger premium, provided the spread is attractive and the merger is highly likely to close.

Keywords

Ventyx Biosciences, Eli Lilly, Merger Agreement, Acquisition, Common Stock, Preferred Stock, Stock Options, RSUs, Cash Consideration, Pharmaceuticals, Biotechnology, Schedule 13D/A